Skip to main content

Table 3 Indications and recommendations of prophylactic use of antibacterial agents for patients with liver cirrhosis or liver failure

From: Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure

  1. Colour coding—blue: indications and recommendations of prophylactic use of antibacterial agents; red: recommendation provided without evidence level and strength; green: first-line prophylactic treatment
  2. CPGs clinical practice guidelines, EASL European Association for the Study of the Liver, CMA Chinese Medical Association, KASL the Korean Association for the Study of the Liver, JSG Japanese Society of Gastroenterology, BSG the British Society of Gastroenterology, APCCMID Asia-Pacific Congress of Clinical Microbiology and Infection Consensus, AASLD the American Association for the Study of Liver Diseases, SIGN Scottish Intercollegiate Guidelines Network, NOR norfloxacin, LVX levofloxacin, CIP ciprofloxacin, MXF moxifloxacin, G3 the third generation cephalosporins, SXT trimethoprim–sulfamethoxazole, RIF rifaximin, CRO ceftriaxone, CTX cefotaxime, GIB gastrointestinal bleeding, ASC ascites (the corresponding indication is patients with ascitic fluid protein lower than 15 g/L), SBP spontaneous bacterial peritonitis (the corresponding indication is patients recovered from spontaneous bacterial peritonitis), CLF chronic liver failure (the corresponding indication is patients with chronic liver failure), PPI perioperative prevention of infections (the corresponding indication is patients in perioperative period before transplantation)
  3. aThe corresponding indication is patients with ascitic fluid protein lower than 15 g/L + severe liver dysfunction or renal insufficiency or hyponatremia severe liver dysfunction or renal insufficiency/hyponatremia
  4. bCo-trimoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim daily, orally)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us